In Alzheimer’s disease, the measurement of mitochondrial biomarkers in cerebrospinal fluid (CSF), such as levels of amyloid-beta, tau, and phosphorylated tau proteins, has shown promise in aiding early diagnosis and tracking disease progression. This evidence concerns the gene MAPT and Alzheimer disease.